These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33435787)

  • 1. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regualting the PI3K/AKT signaling pathway.
    Qiao L; Dong C; Ma B
    J Recept Signal Transduct Res; 2022 Apr; 42(2):151-159. PubMed ID: 33435787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.
    Wang Y; Leng H; Chen H; Wang L; Jiang N; Huo X; Yu B
    Oncol Res; 2016; 24(5):361-369. PubMed ID: 27712593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-543 impairs breast cancer cell phenotypes by targeting and suppressing ubiquitin-conjugating enzyme E2T (UBE2T).
    Li L; Li Q
    Bioengineered; 2021 Dec; 12(2):12394-12406. PubMed ID: 34787051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HYOU1 promotes cell proliferation, migration, and invasion via the PI3K/AKT/FOXO1 feedback loop in bladder cancer.
    Wang W; Jiang X; Xia F; Chen X; Li G; Liu L; Xu Q; Zhu M; Chen C
    Mol Biol Rep; 2023 Jan; 50(1):453-464. PubMed ID: 36348197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer.
    Cui P; Li H; Wang C; Liu Y; Zhang M; Yin Y; Sun Z; Wang Y; Chen X
    J Ovarian Res; 2022 Sep; 15(1):103. PubMed ID: 36088429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUSP28 promotes cell proliferation, migration, and invasion by Akt/β-catenin/Slug axis in breast cancer.
    Zhang J; Guo Y
    Acta Biochim Pol; 2022 Dec; 69(4):711-717. PubMed ID: 36520087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3β/β-catenin pathway.
    Hu W; Xiao L; Cao C; Hua S; Wu D
    Oncotarget; 2016 Mar; 7(12):15161-72. PubMed ID: 26943030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
    Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
    Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
    Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.
    Li Z; Jin Q; Sun Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24406. PubMed ID: 35588431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T.
    Wu Y; Zhang C; Peng D; He S; Huang C; Qian J; Zhu W; Feng N; Gong Y; Li X; Zhou L
    Hum Cell; 2022 Mar; 35(2):542-556. PubMed ID: 35129808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribophorin II promotes the epithelial-mesenchymal transition and aerobic glycolysis of laryngeal squamous cell carcinoma via regulating reactive oxygen species-mediated Phosphatidylinositol-3-Kinase/Protein Kinase B activation.
    Zhou J; Zhang J; Zhang W; Ke Z; Lv Y; Zhang B; Liao Z
    Bioengineered; 2022 Mar; 13(3):5141-5151. PubMed ID: 35156537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
    Zhang J; Yang Y; Dong Y; Liu C
    Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXA1/UBE2T Inhibits CD8
    Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5).
    Li Y; Yang X; Lu D
    Bioengineered; 2022 May; 13(5):11867-11880. PubMed ID: 35543375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEBP1 Contributes to Breast Cancer Progression by Facilitating Cell Proliferation, Migration, Invasion, and Blocking Apoptosis.
    Li J; Ruan Y; Zheng C; Pan Y; Lin B; Chen Q; Zheng Z
    Discov Med; 2023 Feb; 35(174):45-56. PubMed ID: 37024441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53.
    Wu M; Li X; Huang W; Chen Y; Wang B; Liu X
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101493. PubMed ID: 32736946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
    Wang Q; Wu H; Wu Q; Zhong S
    Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.